Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Californian biotech firm Exelixis has submitted an investigational new drug application to the FDA for XL147, a novel anticancer compound.
Subscribe to our email newsletter
The drug is a small molecule inhibitor of phosphoinositide-3 kinase (PI3K). Activation of PI3K is a frequent event in human tumors, promoting tumor cell growth, survival, and resistance to chemotherapy and radiotherapy.
Exelixis is evaluating multiple compounds that inhibit distinct components of the PI3K pathway. The company has already filed applications for two other compounds targeting this pathway, and believes that the strategy has the potential to treat multiple cancers.